Medacta Group (FRA:6MD) Other Stockholders Equity: €32.9 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6MD Medacta Group SA FRA:6MD
93 GF Score
Price €146.00
GF Value €180.03
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medacta Group Other Stockholders Equity?

Medacta Group FRA:6MD 93 Other Stockholders Equity is €32.9 Mil as of Dec. 2025. GuruFocus rates FRA:6MD with a GF Score™ of 93/100 and a GF Value™ of €180.03 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Medacta Group's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €32.9 Mil.

Medacta Group's quarterly Other Stockholders Equity declined from Dec. 2024 (€36.4 Mil) to Jun. 2025 (€31.8 Mil) but then increased from Jun. 2025 (€31.8 Mil) to Dec. 2025 (€32.9 Mil).

Medacta Group's annual Other Stockholders Equity declined from Dec. 2023 (€54.0 Mil) to Dec. 2024 (€36.4 Mil) and declined from Dec. 2024 (€36.4 Mil) to Dec. 2025 (€32.9 Mil).

Medacta Group Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Medacta Group's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medacta Group Other Stockholders Equity Chart

Medacta Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.26 37.16 54.02 36.40 32.95

Medacta Group Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.02 33.54 36.40 31.78 32.95
FRA:6MD
93GF Score
Medacta Group SA FRA:6MD
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medacta Group Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €32.9 Mil mean?
Medacta Group (FRA:6MD) has a Other Stockholders Equity of €32.9 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Medacta Group and its competitors.
Is Medacta Group's Other Stockholders Equity too high?
Medacta Group's current Other Stockholders Equity is €32.9 Mil. Overall, Medacta Group has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Other Stockholders Equity compare to ABT and SYK?
Medacta Group's Other Stockholders Equity of €32.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Medacta Group and its competitors. Medacta Group's current Other Stockholders Equity is €32.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (FRA:6MD) is currently considered Modestly Undervalued. The stock's GF Value™ is €180.03, compared to a current price of €146.00 — trading 18.9% below its estimated fair value. The current Other Stockholders Equity is €32.9 Mil. Medacta Group's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Medacta Group (FRA:6MD), the current Other Stockholders Equity is €32.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medacta Group (FRA:6MD) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued. The current stock price of €146.00 is trading 18.9% below its estimated GF Value™ of €180.03. GuruFocus considers Medacta Group to be Modestly Undervalued.

Key valuation signals for FRA:6MD:

  • Other Stockholders Equity: €32.9 Mil
  • GF Value™: €180.03 vs. price of €146.00 (18.9% below fair value)
  • GF Score™: 93/100 with 2 warning signs

No single metric tells the full story. See the FRA:6MD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medacta Group Business Description

Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
93GF Score

Get the complete analysis for FRA:6MD

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€146.00
Price
€180.03
GF Value